New shot could tame stubborn hives when other treatments fail
NCT ID NCT06162728
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a drug called briquilimab for adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines or omalizumab. The study has three parts, with some participants getting the drug and others a placebo. Researchers are checking safety, how the drug works in the body, and whether it reduces hives and itching.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
briquilimab (a drug given as a shot under the skin)
What this could lead to
If it works, this could offer a new treatment option for people with chronic hives that don't improve with current antihistamines or omalizumab.
What could go wrong
This is an early-phase trial (Phase 1b/2a) with only 88 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 101
Baltimore, Maryland, 21224, United States
-
Site 103
Cincinnati, Ohio, 45236, United States
-
Site 104
Chevy Chase, Maryland, 20815, United States
-
Site 105
San Diego, California, 92123, United States
-
Site 108
Little Rock, Arkansas, 72205, United States
-
Site 109
Boise, Idaho, 83706, United States
-
Site 110
Indianapolis, Indiana, 46250, United States
-
Site 111
Murray, Utah, 84107, United States
-
Site 113
Miami, Florida, 33165, United States
-
Site 115
Seattle, Washington, 98101, United States
-
Site 116
Tampa, Florida, 33613, United States
-
Site 118
Birmingham, Alabama, 35244, United States
-
Site 121
White Marsh, Maryland, 21162, United States
-
Site 122
Overland Park, Kansas, 66210, United States
-
Site 123
Lafayette, Louisiana, 70508, United States
-
Site 124
Springfield, Illinois, 61761, United States
-
Site 201
Berlin, Germany
-
Site 202
Marburg, Germany
-
Site 204
Münster, Germany
-
Site 206
Lübeck, Germany
-
Site 209
Dresden, Germany
-
Site 210
München, Germany
-
Site 211
Buxtehude, Germany